	US 12,409,219 B2
	Recombinant polypeptides containing at least one immunogenic fragment and uses thereof
Fritz M. Schomburg, Madison, WI (US); and David M. Rancour, Madison, WI (US)
Assigned to Boost Biopharma, Inc., Woburn, MA (US)
Filed by Boost Biopharma, Inc., Woburn, MA (US)
Filed on Apr. 25, 2022, as Appl. No. 17/728,798.
Application 17/728,798 is a continuation in part of application No. 17/535,309, filed on Nov. 24, 2021, granted, now 11,358,990.
Application 17/535,309 is a continuation of application No. PCT/US2021/040019, filed on Jun. 30, 2021.
Claims priority of provisional application 63/154,647, filed on Feb. 26, 2021.
Claims priority of provisional application 63/046,426, filed on Jun. 30, 2020.
Prior Publication US 2022/0288194 A1, Sep. 15, 2022
Int. Cl. C07K 14/005 (2006.01); A61K 39/00 (2006.01); A61K 39/215 (2006.01); A61K 47/02 (2006.01); A61P 31/14 (2006.01); C07K 14/165 (2006.01); C07K 16/10 (2006.01)

CPC A61K 39/215 (2013.01) [A61K 47/02 (2013.01); A61P 31/14 (2018.01); C07K 14/165 (2013.01); A61K 2039/55511 (2013.01)]

20 Claims

1. A recombinant polypeptide comprising at least one immunogenic fragment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein comprising an amino acid sequence with at least 93% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 245-254.